Summary
The prevalence of penicillin-resistant pneumococci is increasing worldwide. Methods for susceptibility testing, as well as in vitro susceptibility of penicillin-susceptible and -resistant strains to new and existing agents (including oral and parenteral streptogramins), are described.
For all specimens except CSF, oxacillin screening followed by determination of penicillin minimum inhibitory concentrations (MICs) is satisfactory. For CSF, simultaneous testing of penicillin and cefotaxime or ceftriaxone by E-test is necessary. Of all available oral β-lactams, amoxicillin yields the lowest MICs against penicillin-susceptible and -resistant pneumococci, and is the drug of choice for the treatment of otitis media. Cefotaxime and ceftriaxone yield MICs that are low enough to permit therapy of meningitic and nonmeningitic infections (the former in combination with vancomycin). The higher the strain’s benzylpenicillin (penicillin G) MIC, the more likely it is that simultaneous resistance to nonrelated compounds such as tetracyclines, macrolides, and cotrimoxazole (trimethoprim/sulfamethoxazole) will occur. None of the available quinolones should be used for therapy of pneumococcal infections. Of new and experimental drugs, some of the new quinolones, trovafloxacin, and oral and parenteral streptogramins are promising agents. Imipenem is epileptogenic, but meropenem has potential in the therapy of meningitis. Problematical infections caused by penicillin-resistant pneumococci include meningitis and otitis media. The optimal therapy of the latter two diseases has not yet been clearly delineated.
Similar content being viewed by others
References
Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae. Clin Infect Dis 1992; 15: 77–83.
Munoz R, Coffey TJ, Daniels M, et al. Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae. J Infect Dis 1991; 164: 302–6.
Breiman RF, Butler JC, Tenover FC, et al. Emergence of drugresistant pneumococcal infections in the United States. JAMA 1994; 271: 1831–5.
Block S, Hedrick J, Wright R, et al. Drug-resistant Streptococcus pneumoniae — Kentucky and Tennessee, 1993. Morb Mortal Wkly Rep 1994; 43: 23–5, 31.
Geslin P, Fremaux A, Sissia G, et al. Epidémiologie de la résistance aux antibiotiques de Streptococcus pneumoniae en France. Réseau national de surveillance (1984–1993). Med Mal Infect 1994; 24: 948–61.
Jacobs MR, Bajaksouzian S, Appelbaum PC, et al. Evaluation of the E-test for susceptibility testing of pneumococci. Diagn Microbiol Infect Dis 1992; 15: 473–8.
Fasola E, Bajaksouzian S, Jacobs MR. Variation in erythromycin and clindamycin susceptibility of Streptococcus pneumoniae with four test methods [abstract D13]. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sept 17–20: San Francisco
Jacobs MR, Appelbaum PC. Antibiotic-resistant pneumococci? Rev Med Microbiol 1995; 6 (2): 77–93.
Friedland IR, McCracken Jr GH. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994; 331: 377–82.
Appelbaum PC. New prospects for antibacterial agents against multidrug-resistant pneumococci. Microb Drug Resist 1995; 1: 43–8.
NCCLS. Performance Standards for Antimicrobial Susceptibility Testing; in press. NCCLS, 771 East Lancaster Avenue, Villanova, Pennsylvania 19085
Spangler SK, Jacobs MR, Appelbaum PC. In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those of penicillin G, amoxicillin/clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime and cefdinir. Antimicrob Agents Chemother 1994; 38: 2902–4.
NCCLS. Performance Standards for Antimicrobial Susceptibility Testing; Fifth Informational Supplement. NCCLS document M100-S5 (ISBN1-56238-249-7). NCCLS, 771 East Lancaster Avenue, Villanova, Pennsylvania 19085
Spangler SK, Jacobs MR, Appelbaum PC. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, Win 57273, ofloxacin and ciprofloxacin. Antimicrob Agents Chemother 1992; 36: 856–9.
Pankuch GA, Jacobs MR, Appelbaum PC. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin and vancomycin by using time-kill methodology. Antimicrob Agents Chemother 1994; 38: 2065–72.
Pankuch G, Jacobs M, Appelbaum P. Antipneumococcal activity of RP 59500 (an injectable streptogramin), erythromycin and sparfloxacin by MIC and rapid time-kill [abstract E117]. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sept 17–20: San Francisco
Spangler S, Jacobs M, Appelbaum P. Antipneumococcal activity of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin) and 8 oral β-lactams [abstract F113]. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sept 17–20: San Francisco
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Appelbaum, P.C. Emerging Resistance to Antimicrobial Agents in Gram-Positive Bacteria. Drugs 51 (Suppl 1), 1–5 (1996). https://doi.org/10.2165/00003495-199600511-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199600511-00003